At a glance
ClinicalIndex Comparison RecordN/ACompleted· 94 enrolled
Drug / intervention
Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Compound Silymarin on Biomarkers of Lipid Metabolism and Inflammation in Patients With Non-alcoholic Fatty Liver Disease: A Randomized Controlled Double-blind Trial
In Brief
A clinical study evaluating Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza, Silibinin extract, and 1 other intervention for Nonalcoholic Fatty Liver Disease. Completed, enrolled 94 participants across 1 site.
Detailed Summary
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China. The aim of this project is to evaluate the effects of compound silymarin on biomarkers of lipid metabolism and inflammation in the patients with NAFLD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Fatty Liver Disease
CountriesChina
CollaboratorsAffiliated Hospital of Guangdong Medical University
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartAug 2022
First PostedAug 2022
Primary CompletionJan 2024
Study CompletionFeb 2024
TodayJul 2026
First PostedAug 11, 2022
Enrollment StartAug 1, 2022
Primary CompletionJan 31, 2024
Study CompletionFeb 20, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.9 years ago
Interventions
Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhizadietary
Take 4 tablets with warm water twice a day
Silibinin extractdietary
Take 4 tablets with warm water twice a day
Placebodietary
Take 4 tablets with warm water twice a day